

## PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

## **Phosphodiesterase-5 Inhibitors**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

- I LEAGE NOTE: Any information (patient, processor, aray, tabo) for blank, mogleto, or not attached will acta the review process.		
Patient Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business:   Exchange - PA	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing the enrollee or the enrollee's ability to regain maximum function.	pelow, I certify that the standard review timeframe may seriously jeopardize the life or health of	
Drug Name:		
Strength: Directions / SIG:		
Directions / Sig.		
Please attach any pertinent medical history including labs and information for this member that may support approval.  Please answer the following questions and sign.		
Q1. Is the request for reauthorization? If YE	S, go to 2. If NO, go to 3.	
☐ Yes	□ No	
Q2. Is there confirmation of positive clinical response or stabilization?		
☐ Yes	□ No	
Q3. Is the drug being prescribed by or in consultation with a cardiologist, pulmonologist, practitioner at a Pulmonary Hypertension Association-Accredited center, or rheumatologist?		
☐ Yes	□ No	
Q4. Will the patient take the drug in combination with either of the following: A) Organic nitrates, or B) guanylate cyclase (GC) stimulators (e.g., riociguat)?		
☐Yes	□ No	
Q5. Does the patient have a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH)?		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

## **Phosphodiesterase-5 Inhibitors**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
☐Yes	□ No	
Q6. Has the diagnosis of PAH been confirmed by a complete right heart catheterization (RHC) and are the RHC results provided? PAH defined as:		
o A mean pulmonary artery pressure (mPAP) greater than 20 mmHg o A pulmonary capillary wedge Pressure/ left ventricular end diastolic pressure (PCWPLVEDP) less than or equal to 15 mmHg o A pulmonary vascular resistance (PVR) greater than 2 Wood units.		
☐ Yes	□ No	
Q7. Does the patient have a diagnosis of Raynaud's phenomenon?		
☐ Yes	□ No	
Q8. Has the patient had an inadequate response or intolerance to one calcium channel blocker?		
☐ Yes	□ No	
Q9. Additional Information:		
Prescriber Signature	Date	

v2025